Hemophilia B

A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Children With Hemophilia B
NCT01662531 | PHASE 3 | INTERVENTIONAL

This study will examine the pharmacokinetics, safety and efficacy of rIX-FP for the control and prevention of bleeding episodes in children who have previously received factor replacement therapy for hemophilia B.

Trial Information
17 Sites
27 Participants
Recruiting
18 Years to 11 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

SUBMIT
The Royal Children's Hospital, Melbourne
Parkville,Victoria,Australia,3052
The Children's Hospital at Westmead
Westmead,Australia,2145
AKH Wien (Paediatrics)
Wien,Austria
McMaster Children's Hospital
Hamilton,Ontario,Canada,L8N3Z5
Fakultni nemocnice Brno
Brno,Czech Republic,62500
Fakultni nemocnice Ostrava
Ostrava,Czech Republic,70852
Fakultni nemocnice Motole
Praha 5,Czech Republic,15006
C.R.T.H. Hopital de Bicentre (Hemophilie)
Le Kremlin-Bicentre,France,94275
Hospital Edouard Herriot
Lyon,France,69437
Hpital d'enfants La Timone
Marseille,France,13385
CRC Coagulation Research Center GmbH
Duisburg/Altstadt,Germany,47051
Universittsklinikum Dsseldorf
Düsseldorf,Germany,40225
Sheba Medical Center
Tel Hashomer,Israel,52621
AOU Careggi
Firenze,Italy,50134
IRCCS Ospendale Maggiore (Centro emofilia e Trombosi)
Milano,Italy,20122
FGU "Kirov Research Institute of Haemotology and Blood Trans)
Kirov,Russian Federation,610027
H.U. La Paz
Madrid,Spain,28046

Study Eligibility Criteria

Additional Studies

Additional studies can be found at ClinicalTrials.gov